Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 618.0 -0.02% -0.11
REGN closed up 1.13 percent on Wednesday, January 19, 2022, on approximately normal volume.
Earnings due: Feb 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical REGN trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish -0.02%
Cup with Handle Other -0.02%
Gapped Up Strength -0.02%
Cup with Handle Other 1.11%
Down 3 Days in a Row Weakness 1.11%
20 DMA Resistance Bearish 0.45%
Cup with Handle Other 0.45%
Bearish Engulfing Bearish 0.31%
Fell Below 20 DMA Bearish 0.31%
180 Bearish Setup Bearish Swing Setup 0.31%
Older End-of-Day Signals for REGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 43 minutes ago
Fell Below Previous Day's Low about 1 hour ago
Fell Below 10 DMA about 1 hour ago
20 DMA Resistance about 2 hours ago
Up 1 ATR about 23 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Regeneron Pharmaceuticals, Inc. Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Medicine Biotechnology Biopharmaceutical Nasdaq 100 Immunology Infectious Diseases Clinical Development Pain Antibodies IBD 50 Bone Inflammation Monoclonal Antibodies Disorders Cardiovascular Disease Clinical Research Ophthalmology Macular Degeneration Rheumatoid Arthritis Related Macular Degeneration Vascular Disease Asthma Colorectal Cancer Cholesterol Breakthrough Therapy Dermatitis Macular Edema Syndromes Atopic Dermatitis Lipoprotein Cartilage Angiogenesis Human Monoclonal Antibodies Metastatic Colorectal Cancer Regeneron Allergic Asthma Immune Diseases Intravenous Infusion Muscle Disease Muscle Diseases

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 686.62
52 Week Low 441.0
Average Volume 689,007
200-Day Moving Average 584.70
50-Day Moving Average 632.91
20-Day Moving Average 621.25
10-Day Moving Average 613.68
Average True Range 15.73
ADX 14.15
+DI 25.50
-DI 28.07
Chandelier Exit (Long, 3 ATRs) 604.10
Chandelier Exit (Short, 3 ATRs) 640.04
Upper Bollinger Bands 648.88
Lower Bollinger Band 593.61
Percent B (%b) 0.44
BandWidth 8.90
MACD Line -4.69
MACD Signal Line -4.57
MACD Histogram -0.1211
Fundamentals Value
Market Cap 64.81 Billion
Num Shares 105 Million
EPS 27.29
Price-to-Earnings (P/E) Ratio 22.65
Price-to-Sales 6.24
Price-to-Book 5.26
PEG Ratio 0.96
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 636.29
Resistance 3 (R3) 637.50 632.65 633.26
Resistance 2 (R2) 632.65 628.02 632.05 632.25
Resistance 1 (R1) 625.38 625.16 629.02 624.17 631.24
Pivot Point 620.53 620.53 622.35 619.93 620.53
Support 1 (S1) 613.26 615.90 616.90 612.05 604.98
Support 2 (S2) 608.41 613.04 607.81 603.97
Support 3 (S3) 601.14 608.41 602.96
Support 4 (S4) 599.93